Dr. Nagi El Saghir distinguished as Fellow of the American Society of Clinical Oncology

Safa Jafari Safa, Office of Communications, ss152@aub.edu.lb

 

 
Dr. Nagi El Saghir has been honored as Fellow of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals. The lifetime title was bestowed upon him in recognition of his overall achievements and “extraordinary dedication” to voluntary efforts that benefit the specialty of oncology, patients at risk for or with cancer, and ASCO. 

 
 
[L-R] President of ASCO, Dr. Bruce Johnson, and Dr. El Saghir.


​El Saghir was recognized with the Fellowship Award, previously called statesman award, at the opening session of the annual ASCO meeting in Chicago. The awarding ceremony granted distinction to researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world. 

 
“I am deeply honored and proud to receive this distinguished ASCO Fellowship award (FASCO) that recognizes my contributions and service to ASCO educational activities, research, and care of cancer patients worldwide,” said El Saghir. “It feels good to be appreciated. I see it as another call of duty to continue serving the medical profession, science, patients, and global communities. I love my patients and my medical oncology profession.”

 
He was recently featured as the “internationally renowned expert on the early detection, prevention, and treatment of younger women with breast cancer”  in the ASCOPost magazine, which is known to communicate to oncology professionals and ASCO members highly validated coverage of clinical cancer research, policy news, patient care, clinical practice issues, and thoughtful commentary by leaders in the field of clinical oncology. 

 
Dr. Nagi El Saghir, MD, FACP, FASCO is professor and head of the Division of Hematology Oncology, and director of the Breast Center of Excellence at the Naef K. Basile Cancer Institute (NKBCI) at the American University of Beirut Medical Center (AUBMC).

 
He has made significant contributions and services to patients, physicians, the profession, the community, and the advancement of science at AUB and in Lebanon, the Middle East, and worldwide. A pioneer in the study of epidemiology, etiology, genetic studies, screening, early detection, and management of breast cancer in young women, as well as clinical trials and international consensus guidelines for the treatment of patients with breast cancer.

 
He established and leads AUBMC Breast Center of Excellence and established the Lebanese Breast Cancer Foundation (LBCF) which partners with AUBMC. He is the founding president of the Lebanese Society of Medical Oncology (LSMO) which groups all the cancer specialists in Lebanon and looks after the state of cancer care in Lebanon. He also founded the annual Beirut Breast Cancer Conference (BBCC), which has now become a major regional breast cancer conference for updates and new research presentations. He published over 120 articles in major journals and published a bestseller book ABC of Breast Diseases in Arabic, and organizes breast cancer awareness and screening campaigns all over Lebanon. This has led to a significant down staging of breast cancer in Lebanon and his publications showed that survival of patients with early breast cancer at AUBMC exceeds 80-90% rates, competing with major international cancer centers. El Saghir was recently granted the Cedar National Medal, rank of Officer, from the President of Lebanon and the Excellence in Cancer Research Award from the Lebanese National Center for Scientific Research (CNRS).

 
He has been actively associated with ASCO as a member of several committees, chair of the ASCO international committee, co-chair of Guidelines Advisory Group of Clinical Practice Guidelines Committee, and trainer. He has also been a contributor to multidisciplinary courses, establishment of Society for Medical Oncology (ESMO)/ASCO Global Curriculum recommendations for standard and better training of cancer specialists in Europe and worldwide, and multidisciplinary tumor boards and ASCO Journal editorial boards.​​